Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
LivaNova (LIVN) Stock Price & Analysis
204 Followers
LIVN Stock Chart & Stats
Day’s Range$52.59 - $53.6
52-Week Range― - ―
Previous Close$53.18
Volume13.26K
Average Volume (3M)N/A
Market Cap
$2.85B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 01, 2024EPS Estimate
$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$67.00Price Target Upside27.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
LivaNova News
PremiumCompany Announcements
LivaNova Prices $300M Convertible Notes, Secures Capped Calls
PremiumCompany Announcements
LivaNova PLC Announces $300M Convertible Notes Offering
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessLIVN announced a positive predictive outcome with its OSPREY clinical trial of its aura6000 hypoglossal nerve stimulation device for obstructive sleep apnea, indicating a potential breakthrough in treatment for the millions suffering from the condition.
Financial PerformanceLIVN reported a strong earnings beat driven by growth in its cardiopulmonary segment, demonstrating the company's robust financial health and potential for sustained growth.
Market ExpansionAnalysts have raised the price target for LIVN, reflecting confidence in the company's growth prospects, including market share gains in the Oxygenator market and increased growth in Epilepsy replacements.
Bears Say
Comparative PerformancePrice target is discounted compared to the comp group due to slower EPS CAGR and questions around revenue growth durability into FY25/26.
Management Credibility And Operational PerformanceLong-term risk/reward attractiveness limited by lack of confidence in management's growth direction and need to reverse +5-years of operating margin declines.
Valuation AdjustmentThe target multiple has been reduced from 13.5x EBITDA to 12.5x EBITDA, aligning more with the stock's current and historical trading multiple.
---
Ownership Overview
31.57% Insiders
28.98% Mutual Funds
18.16% Other Institutional Investors
21.29% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
Currently, no data Available
What is LivaNova PLC’s market cap?
Currently, no data Available
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is May 01, 2024 which is in 9 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on Feb 21, 2024. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.1.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is $0.49.
How many shares outstanding does LivaNova PLC have?
Currently, no data Available
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $0.87 in its last earnings report, beating expectations of $0.77. Following the earnings report the stock price went up 8.023%.
Which hedge fund is a major shareholder of LivaNova PLC?
Among the largest hedge funds holding LivaNova PLC’s share is PRIMECAP Management Co. It holds LivaNova PLC’s shares valued at 300M.
---
LivaNova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.00 (27.40% Upside)
$67.00 (27.40% Upside)
Blogger Sentiment
Neutral
LIVN Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 30.5K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
24.86%
12-Months-Change
Fundamentals
Return on Equity
1.41%
Trailing 12-Months
Asset Growth
5.87%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company's shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.
---
LIVN Company Deck
---
LIVN Earnings Call
Q4 2024
0:00 / 0:00
---
LIVN Stock 12 Months Forecast
Average Price Target
$67.00
▲(27.40% Upside)
Technical Analysis
Best Analysts Covering LIVN
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
-2.46%
reiterated a buy rating last month
Copying Michael Matson's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -2.46% per trade.
---